Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD
When choosing a frontline Bruton tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia, clinicians currently rely on FDA‑approved covalent agents, with acalabrutinib and zanubrutinib favored for their superior cardiovascular safety over ibrutinib. Emerging data from the 2025 ASH meeting show that the noncovalent inhibitor pirtobrutinib delivers progression‑free survival comparable to covalent options while markedly reducing atrial fibrillation risk. However, experts caution that using pirtobrutinib first may limit future BTK‑targeted lines because reverse sequencing efficacy remains unproven. Consequently, patient age, risk profile, and anticipated treatment horizon drive the selection strategy.
Infinitus Introduces The First Solution to Evaluate Every Healthcare Interaction Led by AI or Humans
Infinitus Systems launched Lens, a conversation insights engine that evaluates every healthcare interaction—AI or human—by scoring calls against unified criteria. It claims to provide 100% coverage, automatically detecting adverse events, product complaints, and compliance gaps, turning unstructured audio/text into structured...
STAT+: Pharmalittle: We’re Reading About Sanofi and an FDA Voucher, FDA Rethinking a Rejection, and More
Sanofi asked the FDA to withdraw its type 1 diabetes antibody teplizumab from the new fast‑track voucher program after Center for Drug Evaluation and Research director Tracy Beth Høeg publicly challenged a staff decision to approve the drug. The agency missed...
Your Essential 100‑Question Guide to AI in Healthcare
Introducing "100 Questions and Answers About Artificial Intelligence in Healthcare" - your essential guide to understanding the integration of AI and medicine. - Explore 100 essential questions, each offering concise yet insightful answers supported by research and real-world examples. - From the...
BREAKING: Trump Killed Half Of Obamacare While You Were Sleeping
A coalition of congressional measures enacted under the Trump administration has effectively dismantled roughly 70% of the health‑coverage gains made by the Affordable Care Act. The reforms impose 80‑hour monthly work requirements, halve the frequency of eligibility checks, let ACA...
Patient Responsibility Is Rising — The Payment Experience Needs to Keep Up
Patients are now shouldering a larger share of healthcare costs as employers push higher premiums and deductibles, turning the payment experience into a key component of overall care satisfaction. Consumers expect the speed and simplicity of digital checkout, yet many...
SGLT2 Inhibitors Cut Cardiovascular Death by 14%
As a medical school professor: when I trained, "diabetes drugs" meant blood-sugar drugs. That ceiling has been broken. Meta-analysis in Am J Med (Jaiswal et al, U Chicago, Mar 26 2026) pooled 18 RCTs, n=95,913 patients with diabetes, heart failure, or...
Lack of Trust, Not Technology, Is What’s Stopping Health Plans From Meeting Their Mission and Financial Objectives
Health insurers are missing their mission and financial goals because members don’t trust the enrollment and service processes, not because of lacking technology. The upcoming HR1 rule, which adds an 80‑hour‑per‑month work requirement for Medicaid eligibility, turns these trust gaps...
The Cost of Confusion with U.S. Healthcare – a Deja Vu of The Temptations’ “Ball of Confusion”
RevSpring’s new survey of 2,024 U.S. adults reveals pervasive friction in the healthcare journey, with 94% demanding a simpler, more predictable experience. Confusion over costs and insurance dominates patient complaints, while one‑quarter of respondents want payment options that match their...
Studying These Young Alzheimer's Patients Led to Breakthroughs. Trump Cut the Funding
The Dominantly Inherited Alzheimer Network (DIAN) has leveraged over 200 families with rare early‑onset Alzheimer’s gene mutations to uncover how the disease begins and to test amyloid‑targeting drugs that later reached the market. Its international registry, funded by the NIH...
Mont. Air Ambulance Service Seeks $2M for New Helicopter
ALERT, the Montana air‑ambulance service, has secured $3.5 million toward a $5.5 million Bell 429 helicopter and is now seeking the remaining $2 million from the community. The new twin‑engine rotorcraft will replace one of the existing Bell 407s, which will become a backup unit....
Eko Health Appoints Dr. Steven Steinhubl as CMO to Drive Cardiac AI and Global Clinical Strategy
Eko Health has named Dr. Steven R. Steinhubl, a leading cardiologist and digital‑medicine pioneer, as its chief medical officer. In his new role, Steinhubl will direct clinical strategy, research programs, and global partnerships to expand the adoption of Eko’s AI‑enabled...
Newsom Unveils New Behavioral Health Projects to Boost California Wellness
California Governor Gavin Newsom announced a new round of behavioral health infrastructure projects funded by Proposition 1 and the Behavioral Health Continuum Infrastructure Program. The initiative adds residential beds, outpatient services and tribal wellness villages, aiming to curb homelessness and...
STAT+: FDA Revisits a Rare Cancer Treatment It Rejected a Few Months Ago
The FDA has announced it will re‑evaluate a rare‑cancer therapy it dismissed just months earlier, citing new data submitted by the drug’s sponsor. The treatment, aimed at a subtype of metastatic sarcoma, originally failed to meet the agency’s efficacy benchmarks...
NewspointApp Highlights Surge in Paternal Postpartum Depression and Its Hidden Toll
NewspointApp published a feature that underscores the growing prevalence of paternal postpartum depression, estimating it affects 1 in 10 new fathers and up to 1 in 4 when the mother also struggles. The piece cites hormonal shifts, including a 30%...
Restrictive Diets Rewire Brain, Erode Long‑Term Self‑Control, Study Finds
A recent study highlighted by endocrinologist Dr Ravi Shankar Erukulapati and psychologist Dr Sonali Chaturvedi reveals that sustained calorie restriction disrupts ghrelin and leptin balance, rewires the hypothalamus and makes long‑term self‑control harder to maintain. The findings call for flexible,...
Amylyx Pharmaceuticals Q1 Earnings Call Highlights
Amylyx Pharmaceuticals reported that the Phase 3 LUCIDITY trial of its GLP‑1 antagonist avexitide completed dosing and is on track for a top‑line readout in Q3 2026. The company launched a U.S. expanded access program to treat up to 250 adults with...
SSRIs Overprescribed, Numb Minds, Demand Pharma Accountability
Did a bit of reading on SSRIs. They get prescribed like candy. 25% of all women are on them. Numb your mind over time. Can't get off them. Kill sex drive. Turns you into an emotional wreck. Ruins your life. When is...
FDA Launches Real‑Time Clinical Trials to Accelerate Drug Development
The U.S. Food and Drug Administration announced the start of two real‑time clinical trials—one for mantle‑cell lymphoma and another for small‑cell lung cancer—and issued a request for information on a broader pilot program slated for summer 2026. The move aims...
Atara, Pierre Fabre's Cell Therapy to Get Another Shot at FDA Approval
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals are reviving a T‑cell therapy that was rejected twice by the FDA. Regulators have signaled willingness to base a new approval decision on data from a Phase 3 trial, a departure from the earlier requirement...
UK NHS Rolls Out One‑minute Injectable Cancer Therapy, Slashing Visits for 14,000 Patients
The UK National Health Service is replacing two‑hour intravenous pembrolizumab infusions with a one‑minute subcutaneous injection for roughly 14,000 cancer patients each year. The change cuts appointment time by up to 90 % and promises to free clinical capacity while improving...
Artera Launches AI Services Model and Agentic AI Squads for Specialty Care and FQHCs
Artera, formerly WELL Health, has introduced an AI Services Model that replaces generic SaaS with clinic‑specific, agentic solutions. The company deploys AI Service Squads—small teams of AI builders who work alongside providers—to deliver bespoke tools for scheduling, prior authorizations, referral...
Leapfrog 2026 Grades Show Surge in 'A' Hospital Ratings Across U.S.
The Leapfrog Group released its spring 2026 Hospital Safety Grades, reporting a notable rise in 'A' ratings nationwide. Improvements span 17 safety measures, with CPOE compliance climbing to 90% and barcode medication administration to 93%, signaling stronger patient‑safety systems.
Physician Shortages and Licensing
Physician shortages, especially in primary care, are driving long wait times and higher costs for Americans. Health policy analyst Lawson Mansell argues that the shortage is real, citing primary‑care visit delays as a proxy, and points to mismatches in residency...
‘People Should Be Talking About It’: Moves to Curtail Vaccine Information Obscures Important Science, Doctors Say
U.S. health agencies, including the FDA, CDC and NIH, have halted or censored several vaccine studies and presentations in 2026, citing methodological concerns or political language guidelines. A leaked Covid‑19 booster effectiveness study, pulled at the last minute, still shows...
Can Technology Make Home Care Services More Affordable?
CareYaya, founded by Neal Shah, links college‑health students with seniors, offering home‑based care at roughly $20 an hour—about 40% cheaper than traditional agencies that charge $35‑40. The digital platform streamlines booking and payroll, leveraging a workforce of over 50,000 students...
Vertex Secures German Reimbursement for CASGEVY Gene Therapy
Vertex Pharmaceuticals announced a reimbursement agreement with Germany's GKV‑Spitzenverband, granting sustainable access to its CRISPR/Cas9 therapy CASGEVY for patients 12 years and older with sickle cell disease or transfusion‑dependent beta thalassemia. The deal makes Germany the latest market to fund...
Kennedy Denies the One Big Beautiful Bill Act’s Spending Cuts to Medicaid
The Congressional Budget Office projects the One Big Beautiful Bill Act will slash federal Medicaid spending by more than $900 billion over the next decade. Yet Health and Human Services Secretary Robert F. Kennedy Jr. told congressional hearings there are no Medicaid cuts, pointing to a projected...
High Hs‑CRP, Not LDL, Drives Statin Benefit
"But my cholesterol is normal." JUPITER trial (NEJM): 18,000 people, normal LDL, high hs-CRP. Statin → cardiac events ↓44%, heart attacks ↓54%, strokes ↓48%. 322,000-person UK Biobank: hs-CRP outranked LDL. Full episode 🎙 https://youtu.be/FBLB1CQGBPM
Lilly, Gilead Lead Pharma’s M&A Boom
Pharma M&A activity surged in early 2026, with 24 deals announced by April and upfront payments topping $64 billion—almost triple the $24.5 billion recorded in the same period last year. The boom is driven by companies racing to refill pipelines before a...
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Trispecific antibodies are emerging as the next wave of multispecific therapeutics, extending the success of bispecifics by simultaneously engaging three targets. More than 100 candidates are now in clinical trials, with major players such as Pfizer, Sanofi, AbbVie and Johnson...
The Rewards of Repetition
Anthony Guerra, founder of healthsystemCIO, argues that lasting operational excellence stems from tightly documented, repeatable workflows. He draws on Michael Gerber’s "E‑Myth" and the "small‑menu" concept from restaurant management to stress narrowing service scope for mastery. Guerra also highlights that...
Increasing Daily Steps May Boost Recovery After Surgery
Researchers analyzing data from the All of Us Research Program found that postoperative patients who added 1,000 daily steps experienced 18% fewer complications, 16% lower readmission risk, and a 6% reduction in hospital length of stay. The association held across...
Treatment-Resistant IBD May Benefit From New Combo Antibody Therapy
Phase 2b DUET‑Crohn’s and DUET‑UC trials, funded by Johnson & Johnson, tested the fixed‑dose co‑antibody JNJ‑4804 (guselkumab + golimumab) in patients whose IBD had failed prior advanced therapies. In ulcerative colitis, JNJ‑4804 matched guselkumab’s efficacy and outperformed golimumab, while in Crohn’s disease the highest dose...
How to Know You're in Perimenopause and How to Manage It: OB-GYN Tips
Perimenopause, the hormonal transition that precedes menopause, typically begins in a woman's 40s and can last about four years. OB‑GYN Dr. Sheryl Ross explains that irregular periods, hot flashes, mood swings, and memory lapses often signal its onset, but definitive...
Hantavirus Outbreak Threatens Cruise Ship Passengers and Contacts
The #hantavirus outbreak on the cruise ship off the coast of Africa is a serious public health event that needs to be handled properly. But if you are having #Covid flashbacks, put those worries to rest. The risk here is...
Invasive Nanowire BCIs Needed, Non‑Invasive for Biomarkers
I love brain-to-computer interfaces and one of my first papers and granted patents was in AI/ML for BCI. And I was very much impressed with BrainCo's non-invasive BCIs and artificial limbs and sensing fingers (that they sell to Tesla btw)....
Pennsylvania Sues AI Chatbot Company for Posing as a Licensed Doctor
Pennsylvania has filed a lawsuit against Character.AI, accusing the startup of presenting an AI chatbot as a licensed physician in the state. The complaint alleges the bot offered medical advice, misrepresented its credentials, and violated state health‑care regulations. This marks...
HHS Unveils MAHA Action Plan to Slash Psychiatric Overprescribing
On May 4, 2026, HHS Secretary Robert F. Kennedy Jr. introduced the MAHA Action Plan, a federal strategy aimed at curbing the overprescription of psychiatric medications, especially among children. The plan mandates informed consent, shared decision‑making and a shift toward...
Why the ‘Modern Mental Healthcare Maze’ Needs a New Approach
Rula’s annual State of Mental Health report, based on 2,000+ U.S. adults, reveals widening gaps in workplace mental‑health support. It highlights that 43% of employees conceal mental‑health struggles, a behavior known as “masking,” which correlates with higher turnover. The study...
Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 Evuzamitide to Diagnose Cardiac Amyloidosis
Bayer announced that its investigational PET/CT radiotracer I‑124 evuzamitide met the primary sensitivity and specificity endpoints in the Phase III REVEAL trial of 170 adults with suspected cardiac amyloidosis. The study compared the tracer to standard clinical diagnosis and achieved the...
RTC Trial Finds 5‑MTHF Matches Folic Acid, Reduces Unmetabolized Folate
Researchers at the Research Trial Consortium (RTC) reported that a 24‑week randomized trial of 80 pregnant women found prenatal multivitamins containing 5‑MTHF maintained maternal and fetal folate levels on par with folic‑acid formulas, yet produced markedly lower concentrations of unmetabolized...
Parents Reject Newborn Vitamin K Shots, Prompting Infant Deaths Across U.S. Hospitals
ProPublica’s investigation reveals that hospitals nationwide are documenting infant deaths linked to parents refusing the routine vitamin K shot at birth. The trend, driven by misinformation and a desire to avoid perceived medical overreach, has already resulted in multiple fatal bleeding...
Defunded Public Health Fuels Spread of Virus Mutation
I’m not in the business of providing false hope to people. I’m concerned. That mutation of the virus CAN spread from person to person & our current administration has defunded most of public health and people who make vaccines and...
Hidden Microproteins Reshape Our View of Disease
"The human genome encodes for a new category of molecule" "The ‘dark proteome’ is upending our understanding of human disease" @Nature "Expanding the human proteome with microproteins and peptideins" https://t.co/5ncSKGKHBH https://t.co/2Rx65FJCbG @statnews @MeganMolteni https://t.co/7mATxNQ1EO @TheEconomist
GLP-1s: The Numbers that Really Matter for an Effective Health Plan
The BenefitsPRO Broker Expo highlighted a 500% jump in GLP‑1 drug spending, topping $70 billion between 2018 and 2023. Conner Insurance partnered with a wellness coach and a specialty PBM to redesign its diabetes strategy, cutting medical spend by $1 million in...
Climate Change Fuels Emerging Infections; Defunding WHO Is Reckless
No I don’t think so, usually hantaviruses are not as transmissible person-to-person as coronaviruses, but it’s another reminder of the risk of global infections emerging due to climate change, globalization, and why it’s reckless to defund @WHO @CDCgov
Auto-Enrollment in Medicare Advantage Isn’t a Nudge. It’s a Trap
The Trump administration is weighing a policy that would auto‑enroll every new Medicare beneficiary into a private Medicare Advantage (MA) plan, assigning the lowest‑premium option in their ZIP code and locking them in for three years. Proponents label it a...
Sarepta Says to ‘Exercise Prudence’ in Setting Expectations for Elevidys’ Recovery
Sarepta Therapeutics urged analysts to "exercise prudence" as it navigates a turbulent recovery after three patient deaths linked to its Duchenne muscular dystrophy gene therapy Elevidys. The FDA imposed a boxed warning and limited the drug to ambulatory patients aged...
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics reported Q1 2026 results, ending the quarter with $70.1 million in cash and a net loss of $15 million, a sharp improvement from the $28.5 million loss a year earlier. The company highlighted progress on its lead siRNA candidate divesiran, with Phase 2...